Relay Therapeutics Is A Buy For Its Superb Safety Data (NASDAQ:RLAY)

Relay Therapeutics, Inc. (NASDAQ: RLAY ) is working at the cutting edge of precision oncology. RLY-2608, its lead asset, is an allosteric and pan-mutant PI3Kα inhibitor targeting breast cancer. This molecule is currently in phase 3 trials after producingDubai-based investor focused on building a resilient, income-generating portfolio with a long-term growth mindset. My approach is primarily long-only, blending dividend-paying equities, REITs, and other income strategies with selective growth opportunities. ...